Advancing Patient Safety Worldwide: Senzime's Mission to Impact Over 100 Million Patients

At Senzime, our mission is to ensure every patient's journey from anesthesia to recovery is safe and smooth. We’re driving a paradigm shift by developing precision-based monitoring solutions that significantly enhance patient safety in the operating room. Our goal is to ensure that over 100 million patients receive the correct dose of paralytic drugs, are adequately relaxed to enable optimal surgical conditions, and wake up safely and on time.

We are spearheading a clinical and digital transformation, equipping operating rooms around the globe with precise and accurate patient monitoring solutions. To date, we have installed our solutions in thousands of rooms and monitored hundreds of thousands of patients, but there are still over 150,000 operating rooms to go. What sets us apart is our dedication to perfection, the support of our investors, and our shared goals with clinicians worldwide.

Our story began over 50 years ago when a research team at Harvard University introduced a solution to monitor the effects of potentially lethal paralytic drugs - also known as neuromuscular blocking agents - used during anesthesia. This laboratory device measured muscle responses to a series of electrical stimuli, known as train-of-four (TOF).

Twenty years later, the first portable and quantitative TOF monitors were introduced into operating rooms. These devices stimulated patients and monitored the resulting muscle movement to determine the patient’s level of paralysis.

Then in the late 2010’s, following decades of clinical insights, research, and development, Senzime launched the TetraGraph. It was the world's first-ever portable electromyography (EMG)-based quantitative TOF monitor. A revolution using advanced algorithms and disposable sensors to monitor the direct effects of paralytic drugs, in real-time and not relying on muscle movement. This marked a paradigm shift, providing a smart, easy-to-use, and highly accurate solution for securing patient safety in every operating room.

Senzime was not only first to market, but our technology quickly became the new gold standard in leading hospitals worldwide. We also introduced a portfolio of non-invasive, patient-friendly, and biocompatible sensors for stimulation and recording. Our commercial teams' relentless dedication, sustainable production processes, and commitment to long-term innovation make Senzime unique in the industry.

Our journey began with the knowledge that every second, a new patient suffers from post-operative complications due to use of paralytic drugs and inadequate monitoring. Thousands of studies later, the American Society of Anesthesia and the European Society of Anaesthesiology and Intensive Care published practice guidelines recommending quantitative TOF monitoring for all patients receiving paralytic drugs.

Patients undergoing surgery deserve the best, and we are fortunate to be where we are today. Transforming healthcare practices is a journey, and it takes time to establish a new clinical gold standard. We have surpassed the 17-year mark - the typical time it takes to commercialize translational research - and are excited to continue leading the clinical and digital transition for patient safety worldwide.

Join our mission - as a clinical user, patient safety advocate, shareholder, partner, employee, or follower. The impact we are making every day is directly proportional to the value and legacy we create.